Principal Investigator: Sisira Yadala, M.D., Director, Division of Epilepsy; Director, Clinical Neurophysiology Lab, Assistant Professor, Department of Neurology; College of Medicine.
Summary: A phase 3 clinical trial evaluating the efficacy and safety of intravenous Ganaxolone as a potential treatment for refractory status epilepticus, uncontrolled seizures that do not respond to typical first and second line seizure medications.
Significance: Status epilepticus is a serious condition that requires immediate intervention to stop the seizures and prevent permanent brain damage.
TRI Services: Budget development, Medicare coverage analysis, regulatory and research nurse coordinator services.
Sponsor: Marinus Pharmaceuticals Inc.